The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia￼
With transformative treatments that leverage CRISPR gene-editing technology, there are many challenges to overcome throughout the journey of development through to patient access. We interviewed a researcher at a top-20 pharma company, multiple patients, and our own market access experts for their insights into the process, obstacles, and opportunities for biopharmaceutical companies to meet patient needs and achieve success in the market.
Download the free article to:
Access expert opinions and find out how commercialization of novel gene-editing technology in beta-thalassemia could transform patients’ lives with a connected approach that anticipates obstacles and incorporates patient perspectives upfront
Gain insight into the process, obstacles, and opportunities for biopharmaceutical companies to meet patient needs and achieve success in the market
Discover how CRISPR technology could offer a safer, more accessible, and life-changing method of gene therapy for patients with beta-thalassemia if pricing is within reach
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.